Attached files

file filename
8-K - FORM 8-K - FLUIDIGM CORPd661498d8k.htm
EX-99.1 - EX-99.1 - FLUIDIGM CORPd661498dex991.htm
EX-2.1 - EX-2.1 - FLUIDIGM CORPd661498dex21.htm
EX-23.1 - EX-23.1 - FLUIDIGM CORPd661498dex231.htm
EX-99.2 - EX-99.2 - FLUIDIGM CORPd661498dex992.htm
EX-99.3 - EX-99.3 - FLUIDIGM CORPd661498dex993.htm
EX-99.4 - EX-99.4 - FLUIDIGM CORPd661498dex994.htm

Exhibit 10.1

BUSINESS FINANCING MODIFICATION AGREEMENT

This Business Financing Modification Agreement is entered into as of January 29, 2014, by and between Fluidigm Corporation, a Delaware corporation (the “Borrower”), and Bridge Bank, National Association (“Lender”).

1. DESCRIPTION OF EXISTING DOCUMENTS: Borrower and Lender are parties to a Business Financing Agreement, dated December 16, 2010, as amended on February 8, 2011, March 31, 2011, and December 21, 2012 (as may be further amended from time to time, the “Business Financing Agreement”). Capitalized terms used without definition herein shall have the meanings assigned to them in the Business Financing Agreement.

Hereinafter, all indebtedness owing by Borrower to Lender shall be referred to as the “Indebtedness” and the Business Financing Agreement and any and all other documents executed by Borrower in favor of Lender shall be referred to as the “Existing Documents.”

2. DESCRIPTION OF CHANGE IN TERMS.

 

  A. Modifications to Business Financing Agreement:

 

  (1) The following defined terms in Section 12.1 entitled “Definitions” are hereby amended as follows:

Permitted Indebtedness” is amended to add thereto the following new clause (l):

(l) Indebtedness of Borrower consisting of convertible debt securities, in an aggregate principal amount of up to $220,000,000, issued pursuant to an indenture between Borrower and U.S. Bank National Association.

Permitted Liens” is amended to add thereto the following new clause (n):

(n) customary Liens granted in favor of a trustee to secure fees and other amounts owing to such trustee under an indenture or other agreement pursuant to Indebtedness not otherwise prohibited under this Business Financing Agreement.

3. CONSENT TO ACQUISITION. Bank hereby consents to the Borrower’s acquisition of all of the capital stock of DVS Sciences, Inc., a Delaware corporation.

4. CONSISTENT CHANGES. The Existing Documents are each hereby amended wherever necessary to reflect the changes described above.

5. NO DEFENSES OF BORROWER/GENERAL RELEASE. Borrower agrees that, as of this date, it has no defenses against the obligations to pay any amounts under the Indebtedness. Each of Borrower and Guarantor (each, a “Releasing Party”) acknowledges that Lender would not enter into this Business Financing Modification Agreement without Releasing Party’s assurance that it has no claims against Lender or any of Lender’s officers, directors, employees or agents. Except for the obligations arising hereafter under this Business Financing Modification Agreement, each Releasing Party releases Lender, and each of Lender’s and entity’s officers, directors and employees from any known or unknown claims that Releasing Party now has against Lender of any nature, including any claims that Releasing Party, its successors, counsel, and advisors may in the future discover they would have now if they had known facts not now known to them, whether

 

1


founded in contract, in tort or pursuant to any other theory of liability, including but not limited to any claims arising out of or related to the Agreement or the transactions contemplated thereby. Releasing Party waives the provisions of California Civil Code section 1542, which states:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

The provisions, waivers and releases set forth in this section are binding upon each Releasing Party and its shareholders, agents, employees, assigns and successors in interest. The provisions, waivers and releases of this section shall inure to the benefit of Lender and its agents, employees, officers, directors, assigns and successors in interest. The provisions of this section shall survive payment in full of the Obligations, full performance of all the terms of this Business Financing Modification Agreement and the Business Financing Agreement, and/or Lender’s actions to exercise any remedy available under the Business Financing Agreement or otherwise.

6. CONTINUING VALIDITY. Borrower understands and agrees that in modifying the Existing Documents, Lender is relying upon Borrower’s representations, warranties, and agreements, as set forth therein. Except as expressly modified pursuant to this Business Financing Modification Agreement, the terms of the Existing Documents remain unchanged and in full force and effect. Lender’s agreement to modifications to the Existing Documents pursuant to this Business Financing Modification Agreement in no way shall obligate Lender to make any future modifications to the Existing Documents or the Indebtedness. Nothing in this Business Financing Modification Agreement shall constitute a satisfaction of the Indebtedness. It is the intention of Lender and Borrower to retain as liable parties all makers and endorsers of Existing Documents, unless the party is expressly released by Lender in writing. No maker, endorser, or guarantor will be released by virtue of this Business Financing Modification Agreement. The terms of this paragraph apply not only to this Business Financing Modification Agreement, but also to any subsequent modification agreements relating to the Business Financing Agreement.

~~ signatures follow ~~

 

2


IN WITNESS WHEREOF, Borrower and Lender have executed this Agreement on the day and year above written.

 

BORROWER:     LENDER:
FLUIDIGM CORPORATION     BRIDGE BANK, NATIONAL ASSOCIATION
By   

/s/ Vikram Jog

    By  

/s/ Chris Hill

Name:    Vikram Jog     Name:   Chris Hill
Title:    Chief Financial Officer     Title:   Senior Vice President

 

3